CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib-Reference-Cited by-同舟云学术

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib

Published:2021-06-11 Issue:9 Volume:26 Page:1628-1639
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Kato Ryoji,Hayashi Hidetoshi^ORCID,Sakai Kazuko,Suzuki Shinichiro,Haratani Koji,Takahama Takayuki,Tanizaki Junko,Nonagase Yoshikane,Tanaka Kaoru,Yoshida Takeshi,Takeda Masayuki,Yonesaka Kimio,Kaneda Hiroyasu,Nishio Kazuto,Nakagawa Kazuhiko

Funder

Nippon Boehringer Ingelheim

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-021-01947-3.pdf

Reference42 articles.

1. Mok TS, Wu YL, Ahn MJ et al (2017) Osimertinib or Platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629–640. https://doi.org/10.1056/NEJMoa1612674

2. Yang JC, Ahn MJ, Kim DW et al (2017) Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 35(12):1288–1296. https://doi.org/10.1200/JCO.2016.70.3223

3. Oxnard GR, Hu Y, Mileham KF et al (2018) Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol 4(11):1527–1534. https://doi.org/10.1001/jamaoncol.2018.2969

4. Planchard D, Loriot Y, Andre F et al (2015) EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 26(10):2073–2078. https://doi.org/10.1093/annonc/mdv319

5. Ou SI, Nagasaka M, Zhu VW (2018) Liquid biopsy to identify actionable genomic alterations. Am Soc Clin Oncol Educ Book 38:978–997. https://doi.org/10.1200/EDBK_199765

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From haystack to high precision: advanced sequencing methods to unraveling circulating tumor DNA mutations;Frontiers in Molecular Biosciences;2024-08-06

2. Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods;World Journal of Methodology;2024-06-20

3. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay;International Journal of Clinical Oncology;2024-03-29

4. Clinical phase II trial shows that combining osimertinib and afatinib resistance EGFR recurrent mutation in EGFR-mutant lung cancer;Southeast Asian Journal of Health Professional;2024-03-15

5. Genetic alterations predict poor efficacy, outcomes and resistance to second-line osimertinib treatment in non-small cell lung cancer;American Journal of Cancer Research;2024